Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Accumulated Expenses (2019 - 2025)

IDEAYA Biosciences' Accumulated Expenses history spans 7 years, with the latest figure at $40.9 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 34.73% year-over-year to $40.9 million; the TTM value through Dec 2025 reached $40.9 million, up 34.73%, while the annual FY2025 figure was $40.9 million, 34.73% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $40.9 million at IDEAYA Biosciences, up from $30.4 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $40.9 million in Q4 2025 and bottomed at $2.1 million in Q1 2021.
  • The 5-year median for Accumulated Expenses is $4.7 million (2022), against an average of $10.7 million.
  • The largest annual shift saw Accumulated Expenses crashed 62.17% in 2021 before it skyrocketed 335.22% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $12.3 million in 2021, then tumbled by 57.4% to $5.2 million in 2022, then surged by 32.89% to $7.0 million in 2023, then surged by 335.22% to $30.4 million in 2024, then surged by 34.73% to $40.9 million in 2025.
  • Per Business Quant, the three most recent readings for IDYA's Accumulated Expenses are $40.9 million (Q4 2025), $30.4 million (Q4 2024), and $7.0 million (Q4 2023).